NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: CD BioSciences' Comprehensive Anti-Aging Drug Development Services
TL;DR
CD BioSciences offers pharmaceutical companies a competitive edge with comprehensive anti-aging drug development services that accelerate R&D timelines and reduce entry barriers.
CD BioSciences provides a systematic anti-aging drug development process covering target verification, lead compound screening, preclinical models, pharmacology, pharmacokinetics, and safety evaluation.
This service advances anti-aging therapeutics that could extend healthy lifespans and improve quality of life for aging populations worldwide.
CD BioSciences uses diverse aging models including naked mole-rats and zebrafish to test drugs targeting pathways like mTOR and SIRT1.
Found this article helpful?
Share it with your network and spread the knowledge!
CD BioSciences has launched a comprehensive one-stop anti-aging drug development service package that supports partners throughout the entire anti-aging drug development cycle, from early discovery to preclinical stages.
The services are designed for pharmaceutical companies, research institutions, and academic investigators who are developing cutting-edge anti-aging drugs.
Their services cover key molecules and signaling pathways including AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K, which are closely associated with aging mechanisms.
They work with mainstream anti-aging drug categories including senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, anti-inflammatory drugs, antioxidants, telomerase activators, and mitochondrial modulators.
Their preclinical development system includes anti-aging pharmacology services (in vitro and in vivo evaluations), in vitro ADME services, in vivo pharmacokinetic services, in vitro toxicity testing, non-GLP toxicology, and safety pharmacology services.
They offer four major categories of customizable preclinical aging models: organ-specific aging models, general aging models, longevity models, and aging-related disease models, covering everything from cellular senescence models to non-human primate aging models.
The launch addresses the key challenges of lengthy timelines and high barriers to entry in anti-aging R&D, aiming to promote innovation and transformation of anti-aging therapeutics.
You can visit their anti-aging drug development services page or their custom models for preclinical aging research page for more details.
The announcement was made on December 18, 2025, as indicated in the press release.
CD BioSciences aims to become a top-selected partner for worldwide institutions in the field of anti-aging drug development and will continue to optimize its technical platforms and service systems.
Curated from 24-7 Press Release
